Improving combination therapies and defining optimal strategies for advanced lung cancer will be an opportunity to overcome ICIs resistance and wider use of anti-PD-1, anti- PD-L1 and anti-CTLA-4 antibodies. This evidence concerns the gene PDCD1 and lung cancer.